MEDIA CONTACT:
Cindy Geppert 954.543.2134
E-mail: emrahllc2@gmail.com
FOR IMMEDIATE RELEASE:
THE FOUNDATION FOR SICKLE CELL DISEASE RESEARCH
WELCOMES NEW BOARD MEMBER
WILLIAM E. GANNON, JR., MD, MBA
Hollywood, Fla. (June 30, 2013) The Foundation for Sickle Cell Disease Research (FSCDR) is pleased to announce the addition of Dr. William E. Gannon, Jr., as its newest board member. Currently Dr. Gannon serves as Co-Founder/Chief Scientific Officer & Medical Director for Capital City Technical Consulting, Inc. in Washington, DC, and has a wealth of experience in the management of clinical trials including designing the trials and building operational teams to ensure their successful completion.
“I am privileged to join such an esteemed group of colleagues,” says Dr. Gannon, “and I am looking forward to help them further their research and scientific work on Sickle Cell Disease and Thalassemia.”
Dr. Gannon has held positions in multinational CRO’s, medical device, biotech and pharmaceutical firms. In his most recent position prior to CCTC, Inc., He also served as Vice President – Clinical & Medical Affairs in biotechnology arena.
Dr. Gannon’s primary focus has been on oncology therapeutic and diagnostic applications, but possesses a broad range of experience across therapeutic categories and has managed clinical trials and operations as well as the design, corporate and regulatory strategies, regulatory submissions and execution of Phase I through Phase IV clinical trials in the U.S., Europe and Asia.
“We are honored to have Dr. Gannon join our board of directors,” states Foundation President, Lanetta Jordon, MD. “His extensive experience and medical expertise in clinical biotechnology and oncology therapeutic applications will be invaluable to the work of the Foundation for Sickle Cell Disease Research,” says Dr. Jordan.
The Foundation for Sickle Cell Disease Research, based in Hollywood, FL, whose core mission is to support innovative research in Sickle Cell Disease, is in the process of establishing a sickle cell disease and thalassemia electronic health record system which will serve as a registry for patients affected by the disease.
About the symposium:
What began with a national research and educational meeting in 2005 developed into the Foundation for Sickle Cell Disease Research (FSCDR), which currently serves as the forum for the presentation, advancement and dissemination of scientific works in sickle cell disease. The goal of FSCDR is to begin providing research grants in 2015 to support its core mission of innovative research in sickle cell disease and to help ease implementation of evidence-based research with the objective to maximize quality of life and improved survival for patients.
Sickle cell disease is a genetic blood disorder that occurs more commonly in people (or their descendants) from parts of tropical and sub-tropicalsub-Saharan regions where malaria is or was common. Sickle cell disease prevents oxygen from reaching the spleen, liver, kidneys, lungs, heart, or other organs, causing significant damage to the patient’s internal organs.
To learn more or to register to attend the Sickle Cell Disease Research and Educational Symposium and the Annual National Sickle Cell Disease Scientific Meeting visit: http://fscdr.org